Wire Stories
AriBio Announces Completion of Enrollment in Phase 2 Alzheimer�s Study with AR1001
Topline results expected early 2021 SEONGNAM, South Korea–(BUSINESS WIRE)–AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020,...